Medtronic (MDT) Stock Forecast, Price Target & Predictions
MDT Stock Forecast
Medtronic stock forecast is as follows: an average price target of $106.77 (represents a 18.63% upside from MDT’s last price of $90.00) and a rating consensus of 'Hold', based on 18 wall street analysts offering a 1-year stock forecast.
MDT Price Target
The average price target for Medtronic (MDT) is $106.77 based on 1-year price targets from 18 Wall Street analysts in the past 3 months, with a price target range of $165.00 to $80.00. This represents a potential 18.63% upside from MDT's last price of $90.00.
MDT Analyst Ratings
According to 18 Wall Street analysts, Medtronic's rating consensus is 'Hold'. The analyst rating breakdown for MDT stock is 0 'Strong Buy' (0.00%), 8 'Buy' (44.44%), 9 'Hold' (50.00%), 1 'Sell' (5.56%), and 0 'Strong Sell' (0.00%).
Medtronic Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Aug 21, 2024 | David Roman | Goldman Sachs | $82.00 | $86.40 | -5.09% | -8.89% |
| Aug 21, 2024 | Steven Lichtman | Oppenheimer | $94.00 | $86.46 | 8.72% | 4.44% |
| Aug 21, 2024 | Matt O'Brien | Piper Sandler | $90.00 | $85.38 | 5.41% | - |
| Aug 21, 2024 | Anthony Petrone | Mizuho Securities | $98.00 | $86.38 | 13.45% | 8.89% |
| Aug 21, 2024 | Larry Biegelsen | Wells Fargo | $106.00 | $85.38 | 24.15% | 17.78% |
| Aug 20, 2024 | Rick Wise | Stifel Nicolaus | $87.00 | $85.38 | 1.90% | -3.33% |
| May 24, 2024 | David Rescott | Robert W. Baird | $87.00 | $81.91 | 6.21% | -3.33% |
| May 24, 2024 | Shagun Singh | RBC Capital | $92.00 | $81.38 | 13.05% | 2.22% |
| May 24, 2024 | Richard Newitter | Truist Financial | $88.00 | $81.38 | 8.13% | -2.22% |
| May 24, 2024 | Larry Biegelsen | Wells Fargo | $105.00 | $81.38 | 29.02% | 16.67% |
The latest Medtronic stock forecast, released on Aug 21, 2024 by David Roman from Goldman Sachs, set a price target of $82.00, which represents a -5.09% decrease from the stock price at the time of the forecast ($86.40), and a -8.89% decrease from MDT last price ($90.00).
Medtronic Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | 6 | 6 | 11 |
| Avg Price Target | $92.83 | $92.83 | $93.55 |
| Last Closing Price | $90.00 | $90.00 | $90.00 |
| Upside/Downside | 3.14% | 3.14% | 3.94% |
In the current month, the average price target of Medtronic stock is $92.83, according to 6 Wall Street analysts offering twelve months forecast. The average price target represents a 3.14% increase as opposed to Medtronic's last price of $90.00. This month's average price target is down 0.00% compared to last quarter, and down -0.77% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Sep 12, 2024 | Piper Sandler | Neutral | Neutral | Hold |
| Aug 22, 2024 | Barclays | Overweight | Overweight | Hold |
| Aug 21, 2024 | Oppenheimer | Perform | Perform | Hold |
| Aug 21, 2024 | Piper Sandler | Overweight | Overweight | Hold |
| Aug 21, 2024 | Goldman Sachs | Sell | Sell | Hold |
| Aug 21, 2024 | Piper Sandler | Neutral | Neutral | Hold |
| Aug 21, 2024 | Wells Fargo | Overweight | Overweight | Hold |
| Aug 15, 2024 | Cowen & Co. | Buy | Buy | Hold |
| Aug 15, 2024 | UBS | Underperform | Neutral | Upgrade |
| Aug 12, 2024 | Wells Fargo | Sector Perform | Sector Perform | Hold |
Medtronic's last stock rating was published by Piper Sandler on Sep 12, 2024. The company gave MDT a "Neutral" rating, the same as its previous rate.
Medtronic Financial Forecast
Medtronic Revenue Forecast
| Apr 28 | Jan 28 | Oct 27 | Jul 27 | Apr 27 | Jan 27 | Oct 26 | Jul 26 | Apr 26 | Jan 26 | Oct 25 | Jul 25 | Apr 25 | Jan 25 | Oct 24 | Jul 24 | Apr 24 | Jan 24 | Oct 23 | Jul 23 | Apr 23 | Jan 23 | Oct 22 | Jul 22 | Apr 22 | Jan 22 | Oct 21 | Jul 21 | Apr 21 | Jan 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $8.09B | $7.98B | $7.70B | $8.54B | $7.73B | $7.58B | $7.37B | $8.09B | $7.76B | $7.85B | $7.99B | $8.19B | $7.78B |
| Avg Forecast | $10.29B | $9.72B | $9.60B | $9.30B | $9.73B | $9.16B | $9.01B | $8.70B | $9.35B | $8.81B | $8.65B | $8.34B | $8.95B | $8.41B | $8.27B | $7.90B | $8.45B | $7.95B | $7.93B | $7.57B | $8.25B | $7.54B | $7.70B | $7.22B | $8.43B | $7.88B | $7.96B | $7.87B | $8.14B | $7.77B |
| High Forecast | $10.33B | $9.75B | $9.63B | $9.33B | $9.76B | $9.19B | $9.04B | $8.73B | $9.38B | $8.84B | $8.68B | $8.37B | $8.98B | $8.43B | $8.30B | $7.92B | $8.48B | $7.98B | $7.97B | $7.59B | $8.28B | $7.56B | $7.72B | $7.26B | $8.53B | $7.95B | $8.04B | $7.94B | $8.21B | $7.85B |
| Low Forecast | $10.24B | $9.67B | $9.55B | $9.25B | $9.67B | $9.11B | $8.96B | $8.65B | $9.30B | $8.76B | $8.60B | $8.30B | $8.90B | $8.37B | $8.23B | $7.85B | $8.40B | $7.91B | $7.86B | $7.52B | $8.21B | $7.50B | $7.66B | $7.16B | $8.32B | $7.79B | $7.87B | $7.78B | $8.04B | $7.69B |
| # Analysts | 8 | 10 | 9 | 9 | 13 | 9 | 9 | 15 | 9 | 9 | 16 | 8 | 10 | 18 | 18 | 13 | 9 | 9 | 18 | 9 | 9 | 15 | 8 | 10 | 16 | 8 | 13 | 9 | 9 | 10 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.02% | 1.01% | 1.02% | 1.04% | 1.02% | 0.99% | 1.02% | 0.96% | 0.98% | 0.99% | 1.01% | 1.01% | 1.00% |
Medtronic's average Quarter revenue forecast for Apr 24 based on 9 analysts is $8.45B, with a low forecast of $8.40B, and a high forecast of $8.48B. MDT's average Quarter revenue forecast represents a 4.47% increase compared to the company's last Quarter revenue of $8.09B (Jan 24).
Medtronic EBITDA Forecast
| Apr 28 | Jan 28 | Oct 27 | Jul 27 | Apr 27 | Jan 27 | Oct 26 | Jul 26 | Apr 26 | Jan 26 | Oct 25 | Jul 25 | Apr 25 | Jan 25 | Oct 24 | Jul 24 | Apr 24 | Jan 24 | Oct 23 | Jul 23 | Apr 23 | Jan 23 | Oct 22 | Jul 22 | Apr 22 | Jan 22 | Oct 21 | Jul 21 | Apr 21 | Jan 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 8 | 10 | 9 | 9 | 13 | 9 | 9 | 15 | 9 | 9 | 16 | 8 | 10 | 18 | 18 | 13 | 9 | 9 | 18 | 9 | 9 | 15 | 8 | 10 | 16 | 8 | 13 | 9 | 9 | 10 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $1.48B | $2.27B | $2.11B | $2.68B | $2.26B | $2.21B | $1.89B | $2.46B | $2.40B | $2.30B | $1.64B | $2.39B | $2.03B |
| Avg Forecast | $2.84B | $2.68B | $2.65B | $2.56B | $2.68B | $2.52B | $2.48B | $2.40B | $2.58B | $2.43B | $2.39B | $2.30B | $2.47B | $2.32B | $2.28B | $2.18B | $2.88B | $2.19B | $2.19B | $2.09B | $2.62B | $2.08B | $1.68B | $1.99B | $2.42B | $2.25B | $1.52B | $2.25B | $1.78B | $1.21B |
| High Forecast | $2.85B | $2.69B | $2.66B | $2.57B | $2.69B | $2.53B | $2.49B | $2.41B | $2.59B | $2.44B | $2.39B | $2.31B | $2.48B | $2.32B | $2.29B | $2.19B | $3.45B | $2.20B | $2.20B | $2.09B | $3.14B | $2.09B | $2.01B | $2.00B | $2.45B | $2.69B | $1.83B | $2.70B | $2.14B | $1.45B |
| Low Forecast | $2.82B | $2.67B | $2.63B | $2.55B | $2.67B | $2.51B | $2.47B | $2.39B | $2.56B | $2.42B | $2.37B | $2.29B | $2.45B | $2.31B | $2.27B | $2.17B | $2.30B | $2.18B | $2.17B | $2.07B | $2.09B | $2.07B | $1.34B | $1.97B | $2.39B | $1.80B | $1.22B | $1.80B | $1.43B | $966.28M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.68% | 1.04% | 1.01% | 1.03% | 1.09% | 1.32% | 0.95% | 1.02% | 1.07% | 1.51% | 0.73% | 1.34% | 1.68% |
9 analysts predict MDT's average Quarter EBITDA for Apr 24 to be $2.88B, with a high of $3.45B and a low of $2.30B. This is 93.97% upper than Medtronic's previous annual EBITDA (Jan 24) of $1.48B.
Medtronic Net Income Forecast
| Apr 28 | Jan 28 | Oct 27 | Jul 27 | Apr 27 | Jan 27 | Oct 26 | Jul 26 | Apr 26 | Jan 26 | Oct 25 | Jul 25 | Apr 25 | Jan 25 | Oct 24 | Jul 24 | Apr 24 | Jan 24 | Oct 23 | Jul 23 | Apr 23 | Jan 23 | Oct 22 | Jul 22 | Apr 22 | Jan 22 | Oct 21 | Jul 21 | Apr 21 | Jan 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 8 | 10 | 9 | 9 | 13 | 9 | 9 | 15 | 9 | 9 | 16 | 8 | 10 | 18 | 18 | 13 | 9 | 9 | 18 | 9 | 9 | 15 | 8 | 10 | 16 | 8 | 13 | 9 | 9 | 10 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $1.32B | $909.00M | $791.00M | $1.18B | $1.22B | $427.00M | $929.00M | $1.49B | $1.48B | $1.32B | $763.00M | $1.36B | $1.27B |
| Avg Forecast | - | - | - | - | $2.27B | $2.00B | $1.89B | $1.76B | $2.16B | $1.90B | $1.79B | $1.72B | $2.08B | $1.78B | $1.62B | $1.55B | $1.78B | $1.64B | $1.53B | $1.44B | $1.62B | $1.65B | $782.07M | $1.48B | $2.08B | $1.28B | $710.98M | $1.28B | $1.12B | $358.15M |
| High Forecast | - | - | - | - | $2.28B | $2.01B | $1.90B | $1.77B | $2.17B | $1.91B | $1.80B | $1.73B | $2.09B | $1.81B | $1.65B | $1.56B | $2.13B | $1.64B | $1.56B | $1.44B | $1.94B | $1.65B | $938.49M | $1.50B | $2.12B | $1.54B | $853.17M | $1.54B | $1.34B | $429.78M |
| Low Forecast | - | - | - | - | $2.26B | $1.98B | $1.87B | $1.75B | $2.14B | $1.88B | $1.78B | $1.71B | $2.07B | $1.77B | $1.57B | $1.54B | $1.42B | $1.62B | $1.52B | $1.43B | $1.29B | $1.63B | $625.66M | $1.47B | $2.05B | $1.02B | $568.78M | $1.03B | $892.31M | $286.52M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.81% | 0.59% | 0.55% | 0.73% | 0.74% | 0.55% | 0.63% | 0.71% | 1.16% | 1.85% | 0.59% | 1.22% | 3.55% |
Medtronic's average Quarter net income forecast for Apr 24 is $1.78B, with a range of $1.42B to $2.13B. MDT's average Quarter net income forecast represents a 34.47% increase compared to the company's last Quarter net income of $1.32B (Jan 24).
Medtronic SG&A Forecast
| Apr 28 | Jan 28 | Oct 27 | Jul 27 | Apr 27 | Jan 27 | Oct 26 | Jul 26 | Apr 26 | Jan 26 | Oct 25 | Jul 25 | Apr 25 | Jan 25 | Oct 24 | Jul 24 | Apr 24 | Jan 24 | Oct 23 | Jul 23 | Apr 23 | Jan 23 | Oct 22 | Jul 22 | Apr 22 | Jan 22 | Oct 21 | Jul 21 | Apr 21 | Jan 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 8 | 10 | 9 | 9 | 13 | 9 | 9 | 15 | 9 | 9 | 16 | 8 | 10 | 18 | 18 | 13 | 9 | 9 | 18 | 9 | 9 | 15 | 8 | 10 | 16 | 8 | 13 | 9 | 9 | 10 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $2.67B | $2.69B | $2.61B | $2.62B | $2.62B | $2.62B | $2.57B | $2.57B | $2.56B | $2.62B | $2.55B | $2.60B | $2.54B |
| Avg Forecast | $3.44B | $3.25B | $3.21B | $3.11B | $3.25B | $3.06B | $3.01B | $2.91B | $3.13B | $2.95B | $2.89B | $2.79B | $2.99B | $2.81B | $2.77B | $2.64B | $3.08B | $2.66B | $2.65B | $2.53B | $2.80B | $2.52B | $2.61B | $2.41B | $2.84B | $2.55B | $2.37B | $2.45B | $2.23B | $1.89B |
| High Forecast | $3.46B | $3.26B | $3.22B | $3.12B | $3.27B | $3.07B | $3.02B | $2.92B | $3.14B | $2.96B | $2.90B | $2.80B | $3.00B | $2.82B | $2.78B | $2.65B | $3.69B | $2.67B | $2.67B | $2.54B | $3.36B | $2.53B | $3.13B | $2.43B | $2.88B | $3.07B | $2.85B | $2.94B | $2.67B | $2.26B |
| Low Forecast | $3.43B | $3.24B | $3.20B | $3.09B | $3.24B | $3.05B | $3.00B | $2.90B | $3.11B | $2.93B | $2.88B | $2.78B | $2.98B | $2.80B | $2.75B | $2.63B | $2.46B | $2.65B | $2.63B | $2.52B | $2.24B | $2.51B | $2.09B | $2.40B | $2.80B | $2.04B | $1.90B | $1.96B | $1.78B | $1.51B |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.00% | 1.01% | 1.03% | 0.94% | 1.04% | 1.00% | 1.06% | 0.90% | 1.00% | 1.10% | 1.04% | 1.16% | 1.35% |
Medtronic's average Quarter SG&A projection for Apr 24 is $3.08B, based on 9 Wall Street analysts, with a range of $2.46B to $3.69B. The forecast indicates a 15.08% rise compared to MDT last annual SG&A of $2.67B (Jan 24).
Medtronic EPS Forecast
| Apr 28 | Jan 28 | Oct 27 | Jul 27 | Apr 27 | Jan 27 | Oct 26 | Jul 26 | Apr 26 | Jan 26 | Oct 25 | Jul 25 | Apr 25 | Jan 25 | Oct 24 | Jul 24 | Apr 24 | Jan 24 | Oct 23 | Jul 23 | Apr 23 | Jan 23 | Oct 22 | Jul 22 | Apr 22 | Jan 22 | Oct 21 | Jul 21 | Apr 21 | Jan 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 8 | 10 | 9 | 9 | 13 | 9 | 9 | 15 | 9 | 9 | 16 | 8 | 10 | 18 | 18 | 13 | 9 | 9 | 18 | 9 | 9 | 15 | 8 | 10 | 16 | 8 | 13 | 9 | 9 | 10 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $0.99 | $0.68 | $0.59 | $0.89 | $0.92 | $0.32 | $0.70 | $1.11 | $1.10 | $0.98 | $0.57 | $1.01 | $0.95 |
| Avg Forecast | - | - | - | - | $1.75 | $1.54 | $1.46 | $1.36 | $1.67 | $1.46 | $1.38 | $1.32 | $1.60 | $1.37 | $1.25 | $1.20 | $1.45 | $1.26 | $1.18 | $1.11 | $1.55 | $1.27 | $1.28 | $1.12 | $1.56 | $1.37 | $1.29 | $1.32 | $1.42 | $1.15 |
| High Forecast | - | - | - | - | $1.76 | $1.55 | $1.46 | $1.36 | $1.67 | $1.47 | $1.39 | $1.33 | $1.61 | $1.39 | $1.27 | $1.20 | $1.46 | $1.27 | $1.20 | $1.11 | $1.56 | $1.28 | $1.28 | $1.13 | $1.59 | $1.38 | $1.31 | $1.34 | $1.44 | $1.17 |
| Low Forecast | - | - | - | - | $1.74 | $1.53 | $1.45 | $1.35 | $1.65 | $1.45 | $1.37 | $1.32 | $1.59 | $1.36 | $1.21 | $1.19 | $1.44 | $1.25 | $1.17 | $1.10 | $1.54 | $1.26 | $1.27 | $1.11 | $1.54 | $1.35 | $1.27 | $1.30 | $1.40 | $1.13 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.78% | 0.58% | 0.53% | 0.57% | 0.72% | 0.25% | 0.62% | 0.71% | 0.81% | 0.76% | 0.43% | 0.71% | 0.83% |
According to 9 Wall Street analysts, Medtronic's projected average Quarter EPS for Apr 24 is $1.45, with a low estimate of $1.44 and a high estimate of $1.46. This represents a 46.55% increase compared to MDT previous annual EPS of $0.99 (Jan 24).
Medtronic Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| ALGN | Align | $243.73 | $554.38 | 127.46% | Buy |
| TNDM | Tandem Diabetes Care | $43.97 | $84.44 | 92.04% | Buy |
| EW | Edwards Lifesciences | $68.52 | $97.09 | 41.70% | Buy |
| ZBH | Zimmer Biomet | $106.26 | $137.17 | 29.09% | Hold |
| MDT | Medtronic | $90.00 | $106.77 | 18.63% | Hold |
| DXCM | DexCom | $69.51 | $81.86 | 17.77% | Buy |
| PODD | Insulet | $233.87 | $268.60 | 14.85% | Buy |
| ABT | Abbott Laboratories | $116.40 | $129.50 | 11.25% | Buy |
| SYK | Stryker | $370.25 | $305.00 | -17.62% | Buy |
MDT Forecast FAQ
Is Medtronic a good buy?
No, according to 18 Wall Street analysts, Medtronic (MDT) is considered a 'Hold'. The rating consensus is based on 0 'Strong Buy' and 8 'Buy' recommendations, accounting for 44.44% of MDT's total ratings.
What is MDT's price target?
Medtronic (MDT) average price target is $106.77 with a range of $80 to $165, implying a 18.63% from its last price of $90. The data is based on 18 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Medtronic stock go up soon?
According to Wall Street analysts' prediction for MDT stock, the company can go up by 18.63% (from the last price of $90 to the average price target of $106.77), up by 83.33% based on the highest stock price target, and down by -11.11% based on the lowest stock price target.
Can Medtronic stock reach $140?
MDT's highest twelve months analyst stock price target of $165 supports the claim that Medtronic can reach $140 in the near future.
What is Medtronic's current price target trend?
6 Wall Street analysts forecast a $92.83 price target for Medtronic (MDT) this month, up 3.14% from its last price of $90. Compared to the last 3 and 12 months, the average price target increased by 3.14% and increased by 3.94%, respectively.
What are Medtronic's analysts' financial forecasts?
Medtronic's analysts financial forecasts for the fiscal year (Apr 2027) are as follows: average revenue is $36.59B (high $36.71B, low $36.39B), average EBITDA is $10.09B (high $10.12B, low $10.03B), average net income is $7.92B (high $7.95B, low $7.86B), average SG&A $12.24B (high $12.29B, low $12.18B), and average EPS is $6.11 (high $6.13, low $6.06). MDT's analysts financial forecasts for the fiscal year (Apr 2028) are as follows: average revenue is $38.92B (high $39.04B, low $38.7B), average EBITDA is $10.73B (high $10.77B, low $10.67B), average net income is $0 (high $0, low $0), average SG&A $13.02B (high $13.07B, low $12.95B), and average EPS is $0 (high $0, low $0).
Did the MDT's actual financial results beat the analysts' financial forecasts?
Based on Medtronic's last annual report (Apr 2023), the company's revenue was $31.23B, beating the average analysts forecast of $30.71B by 1.69%. Apple's EBITDA was $9.04B, beating the average prediction of $8.36B by 8.16%. The company's net income was $3.76B, missing the average estimation of $5.53B by -32.03%. Apple's SG&A was $10.42B, beating the average forecast of $10.34B by 0.68%. Lastly, the company's EPS was $2.85, missing the average prediction of $5.22 by -45.42%. In terms of the last quarterly report (Jan 2024), Medtronic's revenue was $8.09B, beating the average analysts' forecast of $7.95B by 1.71%. The company's EBITDA was $1.48B, missing the average prediction of $2.19B by -32.38%. Medtronic's net income was $1.32B, missing the average estimation of $1.64B by -19.18%. The company's SG&A was $2.67B, beating the average forecast of $2.66B by 0.44%. Lastly, the company's EPS was $0.99, missing the average prediction of $1.26 by -21.53%